Literature DB >> 20711692

Does rasagiline have a disease-modifying effect on Parkinson's disease?

Shyamal H Mehta1, John C Morgan, Kapil D Sethi.   

Abstract

Entities:  

Year:  2010        PMID: 20711692     DOI: 10.1007/s11910-010-0133-3

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  4 in total

1.  The delayed-start study design.

Authors:  Ralph B D'Agostino
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

2.  Effect of deprenyl on the progression of disability in early Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

Review 3.  Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

Authors:  J Eric Ahlskog; Ryan J Uitti
Journal:  Neurology       Date:  2010-04-06       Impact factor: 9.910

4.  Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

Authors:  Carl E Clarke
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

  4 in total
  1 in total

1.  Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Authors:  Bradley J Robottom
Journal:  Patient Prefer Adherence       Date:  2011-01-20       Impact factor: 2.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.